Fuad El-Hibri and the TAKREEM Achievement Awards
TAKREEM was created as a venue in which to recognize outstanding accomplishments of Arab men and women. Through the TAKREEM Achievement Awards excellence in the Arab world is identified and highlighted, communicating to the level of experience and expertise among organizations and individuals present among Arabs living throughout the world.
Awards are given in ten categories including [...]
In: Arab, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri · Tagged with: Arab world, Emergent BioSolutions, Fuad El-Hibri, Lebanon, Middle East, Takreem Achievement Awards
Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference in London
Emergent BioSolutions Inc. (NYSE: EBS) will be webcasting its presentation at the Jefferies 2011 Global Healthcare Conference in London on Tuesday, September 27, 2011 at 3:40 PM BST. During the presentation, a member of the company’s management team will provide a corporate overview, which may include a discussion of the company’s business activities and financial [...]
In: Chief executive officer, Emergent BioSolutions, Financial Results, Fuad El-Hibri, Healthcare Conference · Tagged with: Business, Chief executive officer, Emergent BioSolutions, Global Healthcare Conference
Fuad El-Hibri Interviewed by Ricardo Karam
Fuad El-Hibri was interviewed a few months ago by Ricardo Karam. This interview was aired in the 2011 season on the Ricardo Karam’sShow, which focuses on successful people from the Arab community. Ricardo Karam is a well known talk show host who has interviewed many high profile people, such as Celine Dion, Charles Aznavour, Paolo [...]
In: Chief executive officer, Emergent BioSolutions, Fuad El-Hibri · Tagged with: Emergent BioSolutions, Fuad El-Hibri, Kofi Annan, Lebanese, Stanford University, United States
Emergent BioSolutions to Present at Wedbush 2011 Life Sciences Conference
ROCKVILLE, Md., Aug 09, 2011 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Wedbush 2011 Life Sciences Conference in New York on Wednesday, August 17, 2011 at 10:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate [...]
In: Chief executive officer, Fuad El-Hibri, Investors · Tagged with: Emergent BioSolutions, Fuad El-Hibri, Investors, Life Sciences Conference, New York Stock Exchange, Webcast
Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax
ROCKVILLE, Md., — Emergent BioSolutions Inc. (NYSE:EBS) announced on June 23rdthat the Singapore Health Sciences Authority (HSA) has approved Emergent’s product license application for the marketing and sale of BioThrax(R) (Anthrax Vaccine Adsorbed) in Singapore. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) to protect against anthrax infection.
“Emergent is [...]
In: Biothrax, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Health Care, U.S. Food and Drug Administration · Tagged with: Anthrax vaccines, Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Singapore Ministry of Health
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors
ROCKVILLE, Md., Jun 13, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its Chairman and Chief Executive Officer, Fuad El-Hibri, has been appointed to serve on the Board of Directors of the U.S. Chamber of Commerce. The U.S. Chamber of Commerce is the world’s largest business federation representing the interests of more [...]
In: Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, entrepreneur · Tagged with: Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, International Biomedical Research Alliance, United States Chamber of Commerce
Emergent BioSolutions’ Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation
ROCKVILLE, Md., Jun 09, 2011 — Emergent BioSolutions Inc. (NYSE:EBS) announced today that its investigational anthrax vaccine, NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The vaccine candidate, also known as AV7909, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with [...]
In: Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, NuThrax, U.S. Food and Drug Administration · Tagged with: anthrax vaccine, Biothrax, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri
Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule
ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S. government under the company’s contract (200-2009-30162) originally written to supply 14.5 million doses of BioThrax to the Strategic National Stockpile. This marks the largest [...]
In: Biothrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, U.S. Food and Drug Administration · Tagged with: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Strategic National Stockpile
Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference
ROCKVILLE, Md., May 25, 2011 — Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be webcasting its presentation at the Jefferies 2011 Global Healthcare Conference in New York on Tuesday, June 7, 2011 at 1:15 PM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate [...]
In: Business, El-Hibri, Financial Performance, Fuad El-Hibri, Healthcare Conference, Investors · Tagged with: Business, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Management, Webcast
Emergent BioSolutions Reports Financial Results for First Quarter 2011
ROCKVILLE, Md., May 05, 2011 (BUSINESS WIRE) — Emergent BioSolutionsInc. (NYSE: EBS) announced its financial results for the first quarter ended March 31, 2011.
For 1Q 2011, total revenues were $18.5 million as compared to $46.8 million in 2010. In addition, for 1Q 2011 the company recorded a net loss of $21.4 million, or $0.61 per [...]
In: BioDefense, Biothrax, Business, Chief executive officer, Chief financial officer, Revenue · Tagged with: BARDA, Biothrax, Emergent BioSolutions, Fuad El-Hibri, Research and development, Revenue
